

RECEIVED

05 2001

administering [antigen presenting cells] to said individual  
antigen presenting cells which (1) express high level of Fas ligand<sup>TECH CENTER 1600/2900</sup>  
resulted from co-infection with AdLoxPFasL and AxCANCre  
adenoviruses, (2) do not express Fas and (3) express said antigen,  
[wherein said cells express Fas ligand and said antigen,] wherein said  
antigen presenting cells induce apoptosis of Fas-positive T-cells  
directed towards said antigen resulting in said induction of systemic  
tolerance to said antigen.

Please amend claim 16 as follows:

16. (twice amended) A method of creating immune-privileged sites in an individual so as to decrease rejection of a graft, comprising the steps of:

extracting antigen presenting cells from donor organ tissue;

introducing Fas ligand into said antigen presenting cells by co-infection with AdLoxPFasL and AxCANCre adenoviruses to produce Fas ligand-expressing antigen presenting cells expressing an antigen specific to said graft;

introducing said Fas ligand-expressing antigen presenting cells expressing an antigen specific to said graft to said individual

[2]